Last reviewed · How we verify
Small kit rhBMP-2 with local autograft
rhBMP-2 (recombinant human bone morphogenetic protein-2) stimulates bone formation and osteoinduction when combined with autologous bone graft material.
rhBMP-2 (recombinant human bone morphogenetic protein-2) stimulates bone formation and osteoinduction when combined with autologous bone graft material. Used for Spinal fusion surgery, Bone defect repair and regeneration.
At a glance
| Generic name | Small kit rhBMP-2 with local autograft |
|---|---|
| Sponsor | Virtua Health, Inc. |
| Drug class | Bone morphogenetic protein (growth factor) |
| Target | BMP receptor type I and II (ALK3/ALK6) |
| Modality | Biologic |
| Therapeutic area | Orthopedic Surgery / Bone Regeneration |
| Phase | FDA-approved |
Mechanism of action
BMP-2 is a growth factor that activates osteoblasts and promotes differentiation of mesenchymal stem cells into bone-forming cells. When delivered locally with autograft bone, it enhances and accelerates bone healing and fusion. This combination leverages both the osteoinductive properties of rhBMP-2 and the structural/cellular support of autologous bone.
Approved indications
- Spinal fusion surgery
- Bone defect repair and regeneration
Common side effects
- Swelling/edema at surgical site
- Infection
- Heterotopic ossification
- Seroma formation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Small kit rhBMP-2 with local autograft CI brief — competitive landscape report
- Small kit rhBMP-2 with local autograft updates RSS · CI watch RSS
- Virtua Health, Inc. portfolio CI